Evidence map›Paper›PMID 42754747›Full record

ReviewCardiovascular engineering and technology2026

Cardiovascular Disease and Androgens: Clinical Trends, Potential Mechanisms, and Considerations for Engineering Solutions.

Madeline N Monroe, Alexander L Curylo, Farshad Amirkhosravi, Eric I Garcia Huitron, George I Ezeokeke, Inioluwa G Ojediran, Jessica K Wang, Sawyer E Cremer, K Jane Grande-Allen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cardiovascular engineering and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Madeline N Monroe *Department of Bioengineering, Rice University, 6100 Main St., MS 142, Houston, TX, 77005, USA.
Alexander L Curylo *Department of Chemical and Biomolecular Engineering, Rice University, Houston, TX, USA.
Farshad Amirkhosravi *Department of Bioengineering, Rice University, 6100 Main St., MS 142, Houston, TX, 77005, USA.
Eric I Garcia HuitronDepartment of Bioengineering, Rice University, 6100 Main St., MS 142, Houston, TX, 77005, USA.
George I EzeokekeDepartment of Bioengineering, Rice University, 6100 Main St., MS 142, Houston, TX, 77005, USA.ORCID http://orcid.org/0009-0005-0668-1905
Inioluwa G OjediranDepartment of Bioengineering, Rice University, 6100 Main St., MS 142, Houston, TX, 77005, USA.
Jessica K WangDepartment of Bioengineering, Rice University, 6100 Main St., MS 142, Houston, TX, 77005, USA.ORCID http://orcid.org/0000-0003-1421-4969
Sawyer E CremerDepartment of Statistics, Rice University, Houston, TX, USA.
K Jane Grande-AllenDepartment of Bioengineering, Rice University, 6100 Main St., MS 142, Houston, TX, 77005, USA. grande@rice.edu.ORCID http://orcid.org/0000-0003-1533-3767

Funding

Cardiovascular Research and Drug Development (CRDD) training programT32HL170967 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Xander H.T. Wehrens, Damian Winston Young · 2024 to 2026
$830k
American Heart Association 18PRE33960074American Heart Association 25DIVSUP1478725Burroughs Wellcome Fund Burroughs Wellcome Fund Physician Scientist Institutional Award to the Texas A&M University Academy of Physician ScientistsNHLBI NIH HHS T32HL170967NSF Directorate for Engineering 1404008NSF Directorate for Engineering 2129088
6 · The paper itself

Abstract

This review summarizes the current understanding of androgen physiology, relationships between androgens and cardiovascular (CV) diseases, and novel engineering approaches to study the effect of androgens on CV system. Testosterone (T), the primary sex hormone in biological males and a potent sex hormone in females, is the androgen of focus for this review. In the cardiovascular system, T signaling is seen through varying genomic and non-genomic mechanisms, which are further detailed in this review. Varying androgen levels in aging adults can significantly impact CVD outcomes, particularly for males. We also consider the implication of exogenous T treatment and androgen deprivation treatments on CVD. Furthermore, androgen-related trends in different CVD processes such as cardiac hypertrophy, congestive heart failure, atherosclerosis, calcific aortic valve disease, and aneurysms are explored. To that end, we present opportunities for novel tissue engineered approaches to discovering mechanisms and potential therapeutic pathways for androgen-related CV conditions.

Indexed as

Androgen deprivationCalcific aortic valve diseaseHypertensionTestosteroneTissue engineering

Identifiers

PMID42754747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.